Interrupting the PD-1 and PD-L1 interaction with immune checkpoint inhibitors (ICIs) has already conferred transformative survival benefits for numerous solid organ malignancies including HNSCC in the recurrent and metastatic setting [32]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.